mupicin ointment
orion pharma ltd. - mupirocin - ointment - 100 mg/5 gm
mupicin 20 mg/g ointment
united laboratories, inc. - mupirocin - ointment - 20 mg/g
mupicin ointment 2%ww
prime pharmaceutical sdn. bhd. - mupirocin -
mupicin 20 mg/ g (2%) topical cream
unilab, inc. - mupirocin - topical cream - 20 mg/ g (2%)
medicianz mupirocin ointment mupirocin 2%w/w, tube
medsurge pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 400; macrogol 3350 - medicianz mupirocin ointment is indicated for the topical treatment of mild impetigo.
mupirocin ointment
quality care products llc - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: s. aureus and s. pyogenes . this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.
mupirocin ointment
physicians total care, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment, 2% is indicated for the topical treatment of impetigo due to: staphylococcus aureus and streptococcus pyogenes . this drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.
mupirocin ointment
teva pharmaceuticals usa, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti
mupirocin ointment
padagis israel pharmaceuticals ltd - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment usp, 2% is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp, 2%. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated popula
mupirocin ointment
e. fougera & co. a division of fougera pharmaceuticals inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the es